Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.54 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.49 |
| ▸ | FEN1 | P39748 | 3/20 | 0.49 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.49 |
| ▸ | NNMT | P40261 | 2/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | FTO | Q9C0B1 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.35 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12961046 | 0.81 | ASIC3 (0.57) | ASIC3ALOX5APFEN1PIK3C3NNMT | |
| SCHEMBL14147612 | 0.79 | ASIC3 (0.55) | ASIC3ALOX5APFEN1PIK3C3NNMT | |
| SCHEMBL8385495 | 0.79 | ASIC3 (0.57) | ASIC3ALOX5APFEN1PIK3C3NNMT | |
| SCHEMBL8388284 | 0.77 | NNMT (0.49) | ASIC3ALOX5APFEN1PIK3C3NNMT | |
| SCHEMBL8385558 | 0.76 | ASIC3 (0.61) | ASIC3ALOX5APFEN1PIK3C3NNMT | |
| SCHEMBL12305720 | 0.74 | ASIC3 (0.52) | ASIC3ALOX5APFEN1PIK3C3NNMT | |
| SCHEMBL8386135 | 0.74 | ASIC3 (0.52) | ASIC3ALOX5APFEN1PIK3C3NNMT | |
| SCHEMBL4796533 | 0.73 | EHMT2 (0.36) | ASIC3ALOX5APFEN1PIK3C3NNMT | |
| SCHEMBL8388712 | 0.73 | ASIC3 (0.62) | ASIC3ALOX5APFEN1PIK3C3NNMT | |
| SCHEMBL10293323 | 0.73 | ASIC3 (0.62) | ASIC3ALOX5APFEN1PIK3C3NNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053177-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-03-01 | — | — | US | disclosed |
| US-7872018-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-7863289-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080221148-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
| US-20080167338-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167338-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | ASIC3 4358/4885ALOX5AP 4050/4885FEN1 2321/4885 |
| US-20120053177-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | ASIC3 4358/4885ALOX5AP 4050/4885FEN1 2321/4885 |
| US-20080221148-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | ASIC3 4358/4885ALOX5AP 4050/4885FEN1 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.